Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback